Strategies for Combination Therapy in Oncology: Part Two – Working with the “Status Quo”
PM360
NOVEMBER 27, 2023
Status Quo: The Core Issue In oncology, it has been the “status quo” for combination therapies to face challenges with respect to pricing and access. Present approaches for value assessment and pricing are designed for monotherapy agents and lack the capacity to capture the value and facilitate sustainable pricing of combinations.
Let's personalize your content